Pfenex, Inc. has awarded Althea Technologies a contract for the cGMP manufacture of circumsporozoite protein (CSP) from Plasmodium falciparum, a malaria vaccine. Althea Technologies will use its cGMP-ready Pfenex Expression Technology-based production process. Processes for several additional malaria antigens are currently being developed at Pfenex. “We are pleased to award this contract to Althea Technologies,” said Bertrand C. Liang, chief executive officer of Pfenex. “Pfene...